Trial Profile

A Phase 2, Open Label, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of CM-101 Administered for 12 Weeks in Adult Subjects with Primary Sclerosing Cholangitis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CM 101 (Primary)
Indications Primary sclerosing cholangitis
Focus Proof of concept; Therapeutic Use
Acronyms SPRING
Sponsors Chemomab Therapeutics

Most Recent Events

15 May 2025 According to a Chemomab Therapeutics media release, data from this study presented as posters at EASL 2025
05 May 2025 According to a Chemomab Therapeutics media release, data from this study was presented at the Distinguished Abstract Plenary session at Digestive Disease Week (DDW 2025) in San Diego, California.
28 Apr 2025 Results published in the Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com